SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sustained rally to a 52-week high and push through a long-watched round-number level are driving attention, with holders celebrating the recovery while skeptics question whether it can hold without a stronger company-specific catalyst. Traders are also watching the upcoming earnings report and pipeline developments for confirmation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on reports that Trump ruled out an immediate U.S. strike on Iran, with many interpreting the news as a possible relief-driven futures bounce while others argue conflict and oil-supply risks are merely delayed. The debate is amplifying an already cautious, volatile outlook ahead of the Fed decision, major tech earnings and inflation data.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus stock-and-warrant offering has intensified concern about shareholder dilution and contributed to a steep selloff, alongside broader weakness in nuclear stocks. Traders are divided between viewing the pullback as a buying opportunity tied to domestic uranium-enrichment demand and worrying that valuation, expansion costs, and execution risks outweigh the long-term HALEU and DOE-contract potential.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

FDA clearance to expand Alpha Taus recurrent glioblastoma REGAIN trial and anticipated follow-up data are driving attention, alongside progress in its pancreatic cancer program. Traders are optimistic about the early GBM signal but acknowledge that it comes from a small cohort and await larger-data validation.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Discussion is focused on the $17.05 million investor settlement: eligible shareholders are being reminded to file claims before the deadline, with a final approval hearing scheduled immediately afterward. Some traders view clearing the legal overhang as a positive, while others emphasize the settlements limited per-share recovery and historical allegations about Twists production and financial disclosures.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure as gold has weakened and rising rate expectations and yields weigh on precious metals and miners. Traders are divided between viewing the pullback and nearby support as a buying opportunity and expecting further losses if support gives way.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Volatile natural-gas futures are driving discussion, with traders weighing winter-weather demand and storage reports against mild-weather forecasts, strong production, and ample supply; pipeline and Freeport disruptions have also sparked sharp moves. Views are split on whether gas can sustain a rebound, while many warn that BOILs leveraged futures exposure and decay make it especially risky to hold.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Iran and broader Middle East tensions could disrupt oil supplies and shipping. Bulls see tight supply and continued geopolitical risk supporting the move, while bears argue the rally may be overextended and could reverse if tensions ease or a deal emerges.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are focused on SQQQ as a leveraged hedge against the Nasdaq, citing tech weakness and concerns that heavy AI spending may not deliver adequate returns, alongside interest-rate and geopolitical risks. Some expect further downside in tech and favor SQQQ, while others caution that its daily leverage can erode value and that a Nasdaq rebound could reverse its gains.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer results for IMDELLTRA plus Imfinzi are drawing attention, with traders focused on the reported survival benefit and potential to expand the drugs role in earlier treatment. The community views the data as a meaningful pipeline catalyst, though some question how much it will change Amgens broader growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic...

Oramed Pharmaceuticals to Join Russell 2000 and Russell 3000 Indexes

Oramed Pharmaceuticals to Join Russell 2000 and Russell 3000 Indexes Oramed Pharmaceuticals to Join Russell 2000 and Russell 3000 Indexes PR Newswire NEW YORK, June 17, 2026 NEW YORK, June 17, 2026 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced...

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating...

Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) will be releasing earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-oramed-pharmaceuticals-inc-stock...

Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 16.2%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 540,151...

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Here's Why

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Above 50-Day Moving Average - Here's What Happened...

LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years

Equity

The company announced it would implement a 1-for-12 reverse stock split effective Feb. 24, 2026.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 644,912 shares, a growth of...

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average - Time to Sell?

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Should You Sell...

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 424,089...

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Oramed Pharmaceuticals, Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The reverse split would reduce the number of outstanding shares from about 18.3 million to around 1.5 million.</li><li>This marks the company’s second reverse stock split since March 2024, when it carried out a 1-for-7 consolidation.</li><li>Lifeward’s board also approved increasing the authorized share capital to 100 million shares.</li></ul>Shares of Lifeward (LFWD) slumped nearly 20% to their all-time low after the company announced it would implement a 1-for-12 reverse stock split effective Feb. 24, 2026.<a href="https://stocktwits.com/symbol/LFWD">LFWD</a> stock will begin trading on a post-split basis the same day under the existing ticker symbol. The move is aimed at boosting the share price to regain compliance with Nasdaq’s $1.00 minimum bid price requirement.<h2 class="st-heading-2">Outstanding Shares To Be Reduced To Around 1.5 Million</h2>The move follows shareholder approval in January, which authorized the board to determine whether to implement a reverse split of the company’s outstanding ordinary shares and, if so, to set the ratio within a range of 1-for-2 to 1-for-12, giving the board full discretion over the outcome.Under the reverse split, every 12 ordinary shares will automatically convert into one share, reducing outstanding shares from about 18.3 million to around 1.5 million. The board also approved increasing the authorized share capital to 100 million shares.This marks the company’s second reverse split in nearly two years. In March 2024, Lifeward completed a 1-for-7 reverse split of its ordinary shares, reducing the number of outstanding shares from around 60.1 million to about 8.6 million.<h2 class="st-heading-2">Partnership With Oramed For Protein Oral Delivery Technology</h2>In January, Lifeward partnered with Oramed Pharmaceuticals (ORMP) to integrate Oramed’s proprietary POD protein oral delivery technology into its platform.Under the terms of the deal, Oramed could acquire up to a 49.99% equity stake in Lifeward. The investment structure is expected to provide Lifeward with access to up to $47 million in capital through a combination of equity, convertible notes, milestone-based funding, and warrant coverage, supporting future growth initiatives.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Meanwhile, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours.Year-to-date, the stock has declined around 25%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spai-stock-reverses-gains-safe-pro-us-government-ai-contract/cZRN7XMR4x0">This AI-Based Defense Company Secured A US Government Contract – So, Why Did The Stock Reverse Pre-Market Gains?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rewalk Robotics Ltd.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$4.13
Prev Close	$4.12
Open	$4.10
Dividend Yield	0.00%
50-Day Moving Average	$4.62
Beta	0.76
Avg. Volume	188,189.29
PE Ratio	1.00

52-Week High	$5.47
52-Week Low	$2.09
Market Capitalization	$171.8M
EPS (Annual)	$1.50
Price to Book	0.54
Revenue Per Employee	$153,846.15

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORMP Fundamentals